Key Pathogenic Factors in Coronavirus Disease 2019–Associated Coagulopathy and Acute Lung Injury Highlighted in a Patient With Copresentation of Acute Myelocytic Leukemia: A Case Report

The role of concurrent illness in coronavirus disease 2019 (COVID-19) is unknown. Patients with leukemia may display altered thromboinflammatory responses. We report a 53-year-old man presenting with acute leukemia and COVID-19 who developed thrombotic complications and acute respiratory distress syndrome. Multiple analyses, including rotational thromboelastometry and flow cytometry on blood and bronchoalveolar lavage, are reported to characterize coagulation and immune profiles. The patient developed chemotherapy-induced neutropenia that may have protected his lungs from granulocyte-driven hyperinflammatory acute lung injury. However, neutropenia also alters viral clearing, potentially enabling ongoing viral propagation. This case depicts a precarious equilibrium between leukemia and COVID-19.

[1]  J. Aguado,et al.  Clinical course and risk factors for mortality from COVID‐19 in patients with haematological malignancies , 2020, European journal of haematology.

[2]  R. Gale,et al.  Cancer increases risk of in-hospital death from COVID-19 in persons <65 years and those not in complete remission , 2020, Leukemia.

[3]  Jianfeng Zhou,et al.  Clinical characteristics of hematological patients concomitant with COVID‐19 , 2020, Cancer science.

[4]  V. García-Gutiérrez,et al.  Poor outcome in patients with acute leukemia on intensive chemotherapy and COVID-19 , 2020, Bone Marrow Transplantation.

[5]  I. Amit,et al.  Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19 , 2020, Nature Medicine.

[6]  M. Konopleva,et al.  Treating Leukemia in the Time of COVID-19 , 2020, Acta Haematologica.

[7]  L. Galli,et al.  Favourable outcome of coronavirus disease 2019 in a 1‐year‐old girl with acute myeloid leukaemia and severe treatment‐induced immunosuppression , 2020, British journal of haematology.

[8]  J. Connors,et al.  COVID-19 and its implications for thrombosis and anticoagulation , 2020, Blood.

[9]  R. Woods,et al.  Neutrophil extracellular traps in COVID-19. , 2020, JCI insight.

[10]  F. Frigieri,et al.  Evaluation of coagulation function by rotation thromboelastometry in critically ill patients with severe COVID-19 pneumonia , 2020, Journal of Thrombosis and Thrombolysis.

[11]  A. Raza,et al.  Rewriting the rules for care of MDS and AML patients in the time of COVID-19 , 2020, Leukemia Research Reports.

[12]  M. Radic,et al.  Neutrophilia and NETopathy as Key Pathologic Drivers of Progressive Lung Impairment in Patients With COVID-19 , 2020, Frontiers in Pharmacology.

[13]  Yan Zhao,et al.  Neutrophil-to-lymphocyte ratio as an independent risk factor for mortality in hospitalized patients with COVID-19 , 2020, Journal of Infection.

[14]  A. Wolberg,et al.  Fibrinogen, red blood cells, and factor XIII in venous thrombosis , 2015, Journal of thrombosis and haemostasis : JTH.

[15]  P. Chiusolo,et al.  The risk of thrombosis in patients with acute leukemia: occurrence of thrombosis at diagnosis and during treatment , 2005, Journal of thrombosis and haemostasis : JTH.